ChemoTech secures US$725.3K growth loan to scale animal-care expansion
What's the deal? Scandinavian ChemoTech, a Swedish medtech company listed on Nasdaq First North Growth Market, has secured a US$725.3K growth loan from an unnamed larger Swedish financial institution. The Lund-based company will use the funds to expand its animal care business in North America and Europe.
ChemoTech develops Tumour Specific Electroporation (TSE), a patented cancer treatment platform for both humans and animals. The loan will go toward strengthening sales, marketing, and recruitment as it scales operations.
The 36-month loan comes on competitive terms, with an interest rate considerably lower than ChemoTech's existing debt. It is interest-only for the first eight months and will be disbursed in two instalments of US$362.6K each.
Why now? Chief executive officer Mohan Frick said the financing became accessible thanks to "strong revenue growth over the past two years." The company wants to grow its installed base of TSE systems and boost treatment frequency at veterinary clinics — a sign it is shifting from R&D mode into commercial scaling.
What could go wrong? ChemoTech is still pre-profitability, and the loan adds leverage to its balance sheet. Expanding into two continents simultaneously stretches resources for a small-cap company. The veterinary oncology market, while growing, remains niche — and convincing clinics to adopt a novel electroporation platform takes time and clinical proof.
The signal: ChemoTech's ability to secure debt financing on competitive terms — rather than dilutive equity — marks a notable shift for a small-cap medtech still on its path to profitability. The company's bet on veterinary oncology as a commercial beachhead, where regulatory barriers are lower and treatment adoption cycles shorter, could build the clinical track record needed to unlock its larger human health ambitions.
Read more: ChemoTech press release
